National Cancer Institute Thesaurus

Last uploaded: February 23, 2024
Preferred Name

Fulvestrant

Synonyms

7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol

Fulvestrant

fulvestrant

FULVESTRANT

Faslodex(ICI 182,780)

ICI 182,780

Faslodex

ICI 182780

ZD9238

Definitions

A synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1379

Accepted_Therapeutic_Use_For

Hormone receptor-positive metastatic breast cancer

ALT_DEFINITION

A drug used to treat certain types of breast cancer in postmenopausal women. It is also being studied in the treatment of other types of cancer. Faslodex blocks estrogen activity in the body and is a type of antiestrogen.

CAS_Registry

129453-61-8

CHEBI_ID

CHEBI:31638

Chemical_Formula

C32H47F5O3S

code

C1379

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

Contributing_Source

CTRP

FDA

GDC

HemOnc

DEFINITION

A synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)

Display_Name

Fulvestrant

FDA_UNII_Code

22X328QOC4

FULL_SYN

7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol

Fulvestrant

fulvestrant

FULVESTRANT

Faslodex(ICI 182,780)

ICI 182,780

Faslodex

ICI 182780

ZD9238

Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C38361

Is_Value_For_GDC_Property

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

label

Fulvestrant

Legacy Concept Name

Fulvestrant

Maps_To

Fulvestrant

NCI_Drug_Dictionary_ID

43053

NSC Number

719276

PDQ_Closed_Trial_Search_ID

43053

PDQ_Open_Trial_Search_ID

43053

Preferred_Name

Fulvestrant

prefixIRI

Thesaurus:C1379

Semantic_Type

Organic Chemical

Pharmacologic Substance

UMLS_CUI

C0935916

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C2116

Delete Subject Author Type Created
No notes to display